Alumis Inc. announced positive Phase 3 results for envudeucitinib, an oral TYK2 inhibitor, demonstrating rapid and durable improvements in moderate-to-severe plaque psoriasis, including scalp clearance, itch relief, and quality of life. The ONWARD program showed a 54% complete skin clearance rate at 48 weeks, the highest among oral therapies. Patients switching from placebo or apremilast achieved similar benefits to continuous treatment. Alumis plans to submit a New Drug Application (NDA) for envudeucitinib in the fourth quarter of 2026, aiming to offer a leading oral treatment option for psoriasis.
Alumis' new Phase 3 data on envudeucitinib shows a 54% complete skin clearance rate at 48 weeks. For readers following health-sector stocks, here is Pluang's market snapshot as of Oct 09, 2026 14:41 WIB: Among 128 priced US health stocks, 62 rose and 62 fell. Notable movers include DFTX at USD 34.01 with 0% Sell / 100% Buy order activity, CTXR at USD 0.49 with 98% Sell / 2% Buy, and CAH at USD 238.84 with 0% Sell / 100% Buy.
ZenaTech introduced Stacklens™, AI-powered smart safety glasses designed for field technicians and industrial workers, integrating hands-free AI assistance, real-time video support, and thermal imaging. The glasses aim to improve efficiency by allowi...
Polkadot (DOT) experienced a notable price surge on October 10, 2026, driven by broad market factors rather than any confirmed project-specific news. The rally appears linked to increased risk appetite, short-covering, and technical breakouts common ...
Last week saw two biotech companies successfully price their IPOs, alongside a billion-dollar data center developer, an emerging markets fintech, and a dental treatment company. Despite market caution limiting some IPO activity, biotechs remain activ...
The XRP Ledger patched a critical vulnerability in its payment engine that could have allowed attackers to create and spend XRP beyond the network's 100 billion token supply. The flaw, present in versions 3.4.0 and earlier, was fixed in version 3.4.1...
A decade-old bug in the XRP Ledger's payment system could have allowed attackers to create and spend new XRP tokens without funding them, violating the fixed supply of 100 billion XRP. The vulnerability involved a counting error in the ledger's built...
